biostudies-literaturePadmapriyadarsini CIndia TB Research Consortium - Indian Coucnil of Medical ResearchWorld Health OrganizationOpen source Pharma Foundatione024363https://www.ebi.ac.uk/biostudies/studies/S-EPMC6429929biostudies-literatureUnknown9(3)<h4>Introduction</h4>Shorter duration of treatment for the management of drug-susceptible pulmonary tuberculosis (TB) would be a significant improvement in the care of patients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach this goal. This study's objective is to assess the efficacy and safety of metformin-containing anti-TB treatment (ATT) regimen in comparison to the standard 6-month ATT regimen in the treatment of patients with newly diagnosed sputum smear-positive drug-sensitive pulmonary TB.<h4>Methods and analysis</h4>We are conducting a multicentric, randomised open-label controlled clinical trial to achieve the study objective. The intervention group will receive isoniazid (H), rifampicin (BMJ openEvaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.PMC6429929001Natrajan MGuleria RPadmapriyadarsini CKumar HSwaminathan SJawahar SMSingh MGomathy SNBhavani PKPonnuraja CBalganesh TfalseEvaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.<h4>Introduction</h4>Shorter duration of treatment for the management of drug-susceptible pulmonary tuberculosis (TB) would be a significant improvement in the care of patients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach this goal. This study's objective is to assess the efficacy and safety of metformin-containing anti-TB treatment (ATT) regimen in comparison to the standard 6-month ATT regimen in the treatment of patients with newly diagnosed sputum smear-positive drug-sensitive pulmonary TB.<h4>Methods and analysis</h4>We are conducting a multicentric, randomised open-label controlled clinical trial to achieve the study objective. The intervention group will receive isoniazid (H), rifampicin (2019-01-01T00:00:00Z2019 Mar2026-05-07T05:54:30.463Z2019-08-04T07:38:07ZS-EPMC64299293082676110.1136/bmjopen-2018-024363